B6-huAPRIL (huTNFSF13) Mouse
제품명
B6-huAPRIL (huTNFSF13) Mouse
제품 ID
C001852
품종 계통
C57BL/6NCya-Tnfsf13tm1(hTNFSF13)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “B6-huAPRIL (huTNFSF13) Mouse (카탈로그 번호 C001852)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
유전자명
유전자 별칭
APRIL, CD256, TALL2, ZTNF2, TALL-2, TNLG7B, TRDL-1, UNQ383/PRO715
NCBI ID
염색체
Chr 17
MGI ID
Datasheet
품종 계통 설명
The TNFSF13 gene, also known as APRIL (a proliferation-inducing ligand), encodes a critical member of the tumor necrosis factor (TNF) superfamily. Its expression is detected in various cell types within the immune and stromal compartments, including monocytes, macrophages, dendritic cells, and bone marrow precursors [1]. The encoded cytokine functions by binding to specific receptors, namely TNFRSF17/BCMA and TNFRSF13B/TACI, thereby regulating key aspects of B cell and plasma cell biology, including their development and long-term survival. TNFSF13 is instrumental in the adaptive immune response, facilitating antibody class switching and providing essential survival cues to antibody-secreting cells [2]. Dysregulated TNFSF13 expression has been etiologically linked to various pathologies. Aberrant TNFSF13 signaling contributes to the pathogenesis of multiple myeloma and chronic lymphocytic leukemia (CLL) by promoting the proliferation and survival of malignant cells [3]. Furthermore, its dysregulation is also implicated in the progression of several autoimmune disorders, such as rheumatoid arthritis (RA), IgA nephropathy, and systemic lupus erythematosus (SLE) [4].
The B6-huAPRIL (huTNFSF13) mouse is a humanized model constructed via gene-editing technology. The sequence from the ATG start codon to the TGA stop codon of mouse Tnfsf13 is replaced with the sequence from the ATG start codon to the TGA stop codon of human TNFSF13. B6-huAPRIL (huTNFSF13) mice can be used for research into the pathogenesis of autoimmune disorders like rheumatoid arthritis (RA), IgA nephropathy, and systemic lupus erythematosus (SLE), as well as some cancers, and for the development of TNFSF13-targeted drugs.
Reference
Chen R, Wang X, Dai Z, Wang Z, Wu W, Hu Z, Zhang X, Liu Z, Zhang H, Cheng Q. TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas. Front Immunol. 2021 Oct 12;12:713757.
Poznyak AV, Gerasimova EV, Orekhov NA, Karimova AE, Vergun MA, Lapshina KO, Sukhorukov VN, Orekhov AN. Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome. Front Immunol. 2025 Aug 1;16:1523392.
Ullah MA, Mackay F. The BAFF-APRIL System in Cancer. Cancers (Basel). 2023 Mar 16;15(6):1791.
Muto M, Suzuki H, Suzuki Y. New Insights and Future Perspectives of APRIL in IgA Nephropathy. Int J Mol Sci. 2024 Sep 26;25(19):10340.
변형 전략
The sequences from the ATG start codon to the TGA stop codon of the endogenous mouse Tnfsf13 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human TNFSF13 gene. The Neo cassette was inserted downstream of the TGA stop codon. The function of the mouse Tnfsfm13 and Tnfsf13os genes will be affected.
Figure 1. Gene editing strategy of B6-huAPRIL (huTNFSF13) mice.
응용 분야
TNFSF13-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of certain cancers;
Research on the pathological mechanisms and therapeutic approaches of autoimmune disorders, such as rheumatoid arthritis (RA), IgA nephropathy, and systemic lupus erythematosus (SLE).
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.